ClinicalTrials.Veeva

Menu
E

Evolution Research Group | Endeavor Clinical Trials

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

HTX-011
Acetaminophen
Ibuprofen
VX-548
Bupivacaine HCl
LY3841136
Propofol
Bupivacaine Hydrochloride
HSK3486
Tirzepatide

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

20 of 92 total trials

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various...

Enrolling
Overweight
Obesity
Drug: LY3305677
Drug: LY3549492

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing...

Active, not recruiting
Analgesia
Drug: HTX-011
Drug: Acetaminophen

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14...

Active, not recruiting
Post Operative Pain
Drug: 0.25 % Bupivacaine HCl
Drug: Methocarbamol

The purpose of this study is to evaluate the efficacy, safety, tolerability and pharmacokinetics of VX-993 in treating acute pain after a bunionectom...

Enrolling
Acute Pain
Drug: VX-993
Drug: Placebo (matched to HB/APAP)

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate weight management efficacy and safet...

Active, not recruiting
Overweight and Obesity
Obesity
Drug: Placebo
Drug: LY3841136

The main purpose of this study is to evaluate the safety, tolerability of LY4086940 and how it is processed in the body.Participation in Part A of th...

Not yet enrolling
Overweight
Healthy
Drug: LY4086940
Drug: Placebo

The main purpose of this study is to see how orforglipron affects the amount of body fat compared with placebo in participants with obesity or overwe...

Active, not recruiting
Overweight
Obesity
Drug: Orforglipron
Drug: Placebo

The goal of this clinical trial is to learn about the effect of the study drug (ZT-01) on low blood sugar (hypoglycemia) in adults with type 1 diabet...

Enrolling
Type 1 Diabetes Mellitus with Hypoglycemia
Drug: Placebo
Drug: ZT-01, 22 mg

The purpose of this study is to evaluate the efficacy of lepodisiran in reducing cardiovascular risk in participants with high lipoprotein(a) who hav...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Elevated Lp(a)
Drug: Lepodisiran Sodium
Drug: Placebo

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with...

Active, not recruiting
Overweight
Obesity
Drug: Placebo
Drug: LY3549492

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to investigate the safety and efficacy of LY3841136...

Enrolling
Overweight
Obesity
Drug: Placebo
Drug: LY3841136

This is a Phase 2 study to evaluate the safety and efficacy of 24, 36, and 48 mg GZR18 (Q2W) compared with placebo and 15 mg tirzepatide (QW). The st...

Not yet enrolling
Obesity and Overweight
Drug: GZR18
Drug: Tirzepatide

Phase 2 Trial of BMF-219 in Participants with Type 1 Diabetes Mellitus.

Active, not recruiting
Type 1 Diabetes Mellitus
Drug: BMF-219
Locations recently updated

The goal of the ATX101-TKA-004 clinical trial aims to evaluate the efficacy and safety of ATX101 1,500 mg in participants undergoing primary unilater...

Enrolling
Total Knee Arthroplasty (Postoperative Pain)
Drug: ATX101
Drug: bupivacaine hydrochloride

This Phase 1b study of DISC-0974 will assess the safety, tolerability, pharmacokinetics (PK) and Pharmacodynamics (PD) of DISC-0974 in adult particip...

Enrolling
Anemia of Chronic Kidney Disease
Chronic Kidney Diseases
Drug: DISC-0974
Drug: Placebo

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

A study to investigate the use of combination therapy with two investigational products for the treatment of adult patients with Nonalcoholic steatoh...

Enrolling
NASH
Drug: K-877-ER
Drug: Placebo

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent...

Enrolling
Atherosclerotic Cardiovascular Disease (ASCVD)
Chronic Kidney Disease (CKD)
Drug: Retatrutide
Drug: Placebo

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety o...

Enrolling
Hyperuricemia
Gout Flare
Drug: Placebo
Drug: Tigulixostat

This study is evaluating the analgesic efficacy of intravenous (IV) tramadol (AVE-901) compared to placebo in the management of postoperative pain fo...

Active, not recruiting
Pain Management
Drug: Morphine
Other: Placebo

Trial sponsors

Lilly logo
H
Vertex Pharmaceuticals logo
A
Haisco Pharmaceutical Group logo
B
Dexcom logo
I
Integra LifeSciences logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems